IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that it has received tacit clinical trial approval from the National Medical Products Administration (NMPA) for its investigational therapy, RD118. RD118 is a fully human GPRC5D-targeted chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of relapsed/refractory multiple myeloma (r/r MM).
RD118 is an autologous T-cell immunotherapy product that targets G protein-coupled receptor class C group 5 member D (GPRC5D). It is designed to identify and eliminate malignant tumor cells that express GPRC5D. Notably, GPRC5D is highly expressed on multiple myeloma cells but has limited expression in normal tissues, primarily restricted to plasma cells and hair follicle cells. This distinct expression pattern renders GPRC5D a potentially safe and effective target for multiple myeloma treatment.- Flcube.com
